Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub

Therapeutic Classification

nrti Registry

Clinical reference for nrti medications. Access safety monographs, dosing adjustments, and drug-drug interactions for all registered brand names and generics in this class.

Registered Medications (nrti)

This therapeutic registry is dynamically synthesized from professional clinical sources. Listing of a medication does not imply equivalence; refer to individual monographs for head-to-head pharmacological data.

MedicationTherapeutic ClassMaternal Safety

ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE

Trimethoprim/sulfamethoxazole increases lamivudine exposure Severe acute exacerbations of hepatitis B have been reported upon discontinuation.

NRTI

safe

ABACAVIR AND LAMIVUDINE

Use during pregnancy only if potential benefit justifies risk. Available data from the Antiretroviral Pregnancy Registry show no increased risk of birth defects. Monitor for hepatic decompensation in women co-infected with HBV.

NRTI

safe

ABACAVIR SULFATE AND LAMIVUDINE

Abacavir and lamivudine are both FDA Pregnancy Category C. Use during pregnancy only if potential benefit justifies potential risk. No adequate and well-controlled studies in pregnant women. Antiretroviral Pregnancy Registry data for abacavir do not suggest a major teratogenic risk; lamivudine also shows no increased birth defects in registry. However, cases of lactic acidosis and hepatotoxicity have been reported in pregnant women receiving NRTIs. Recommend using in pregnancy only if clearly needed and with close monitoring.

NRTI

safe

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

Use during pregnancy only if clearly needed; sufficient data in humans (zidovudine and lamivudine are well-studied) show no increased risk of major birth defects; abacavir has minimal data but is considered acceptable if HLA-B*5701 negative. The combination is a recommended option in certain guideline-based regimens for pregnant women.

NRTI

safe

ABACAVIR SULFATE; LAMIVUDINE

Pregnancy: Antiretroviral therapy is recommended for HIV-infected pregnant women to prevent vertical transmission. Abacavir/lamivudine is a preferred NRTI backbone in pregnancy, with extensive safety data.

NRTI

safe

ABACAVIR, DOLUTEGRAVIR AND LAMIVUDINE

Abacavir/dolutegravir/lamivudine is recommended as a first-line regimen for HIV-1 during pregnancy, with no evidence of increased teratogenicity. Dolutegravir has been associated with a small increased risk of neural tube defects when taken at conception, but the overall risk is low.

NRTI

safe

ABACAVIR; LAMIVUDINE

Abacavir/lamivudine is generally avoided during pregnancy unless the benefit outweighs the risk; limited data in pregnancy. Antiretroviral Pregnancy Registry data do not show an increased risk of major birth defects overall, but abacavir has been associated with a possible small increased risk of cleft lip/palate in some studies, though not confirmed. Use only if clearly needed.

NRTI

safe

ATAZANAVIR SULFATE;RITONAVIR;LAMIVUDINE;ZIDOVUDINE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

NRTI

safe

BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

CABENUVA KIT

Comprehensive clinical and safety monograph for CABENUVA KIT (CABENUVA KIT).

Antiretroviral (HIV Integrase Inhibitor + NNRTI)

caution

COMBIVIR

Comprehensive clinical and safety monograph for COMBIVIR (COMBIVIR).

Antiretroviral (NRTI Combination)

caution

COMPLERA

Comprehensive clinical and safety monograph for COMPLERA (COMPLERA).

Antiretroviral (NRTI + NNRTI Combination)

caution

DIDANOSINE

Drugs that cause pancreatitis or peripheral neuropathy increase risk Can cause severe pancreatitis and peripheral neuropathy.

NRTI

safe

DOLUTEGRAVIR AND LAMIVUDINE

Trimethoprim/sulfamethoxazole increases lamivudine exposure Severe acute exacerbations of hepatitis B have been reported upon discontinuation.

NRTI

safe

DOLUTEGRAVIR SODIUM AND ABACAVIR SULFATE AND LAMIVUDINE

Trimethoprim/sulfamethoxazole increases lamivudine exposure Severe acute exacerbations of hepatitis B have been reported upon discontinuation.

NRTI

safe

DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

DOLUTEGRAVIR, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

DOLUTEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR ALAFENAMIDE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

DOVATO

Comprehensive clinical and safety monograph for DOVATO (DOVATO).

Antiretroviral (INSTI and NRTI combination)

caution

EDURANT

Comprehensive clinical and safety monograph for EDURANT (EDURANT).

NNRTI Antiretroviral

caution

EDURANT PED

Comprehensive clinical and safety monograph for EDURANT PED (EDURANT PED).

NNRTI Antiretroviral

caution

EFAVIRENZ

Induces CYP3A4 and inhibits CYP2C9/CYP2C19 affecting many drugs Can cause severe psychiatric symptoms and rash.

NNRTI

avoid

EFAVIRENZ 200MG SCORED TABLETS

Induces CYP3A4 and inhibits CYP2C9/CYP2C19 affecting many drugs Can cause severe psychiatric symptoms and rash.

NNRTI

avoid

EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

EMTRICITABINE

Comprehensive clinical and safety monograph for EMTRICITABINE (EMTRICITABINE).

Antiretroviral, NRTI

caution

EMTRICITABINE AND TENOFOVIR ALAFENAMIDE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

EMTRICITABINE; RILPIVIRINE; TENOFOVIR ALAFENAMIDE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

EMTRICITABINE; TENOFOVIR ALAFENAMIDE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

EMTRIVA

Comprehensive clinical and safety monograph for EMTRIVA (EMTRIVA).

Antiretroviral, NRTI

caution

EMZAHH

Comprehensive clinical and safety monograph for EMZAHH (EMZAHH).

Antiretroviral, Integrase Inhibitor + NRTIs

caution

EPIVIR

Comprehensive clinical and safety monograph for EPIVIR (EPIVIR).

NRTI Antiretroviral

caution

EPIVIR-HBV

Comprehensive clinical and safety monograph for EPIVIR-HBV (EPIVIR-HBV).

NRTI Antiviral

caution

EPZICOM

Comprehensive clinical and safety monograph for EPZICOM (EPZICOM).

NRTI Antiretroviral

caution

ETRAVIRINE

Comprehensive clinical and safety monograph for ETRAVIRINE (ETRAVIRINE).

NNRTI Antiretroviral

caution

HIVID

Comprehensive clinical and safety monograph for HIVID (HIVID).

Antiretroviral (NRTI)

caution

INTELENCE

Comprehensive clinical and safety monograph for INTELENCE (INTELENCE).

NNRTI Antiretroviral

caution

JULUCA

Comprehensive clinical and safety monograph for JULUCA (JULUCA).

HIV Integrase Inhibitor / NNRTI Combination

caution

LAMIVUDINE

Trimethoprim/sulfamethoxazole increases lamivudine exposure Severe acute exacerbations of hepatitis B have been reported upon discontinuation.

NRTI

safe

LAMIVUDINE AND STAVUDINE

Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.

NRTI

safe

LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

LAMIVUDINE AND ZIDOVUDINE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

NRTI

safe

LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

NRTI

safe

LAMIVUDINE, NEVIRAPINE, AND STAVUDINE

Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.

NRTI

safe

LAMIVUDINE, ZIDOVUDINE TABS 150MG/300MG CO-PACKAGED WITH NEVIRAPINE TABS 200MG

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

NRTI

safe

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

NRTI

safe

LAMIVUDINE; STAVUDINE

Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.

NRTI

safe

LAMIVUDINE; STAVUDINE; NEVIRAPINE

Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.

NRTI

safe

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

LAMIVUDINE; ZIDOVUDINE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

NRTI

safe

LAMIVUDINE; ZIDOVUDINE; ABACAVIR

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

NRTI

safe

LAMIVUDINE; ZIDOVUDINE; EFAVIRENZ

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

NRTI

safe

LAMIVUDINE; ZIDOVUDINE; NEVIRAPINE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

NRTI

safe

LAMIVUDINE/NEVIRAPINE/ZIDOVUDINE TABLETS

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

NRTI

safe

Lamivudine/Zidovudine 150 mg/300 mg Tablets Co-packaged with Nevirapine 200 mg Tablets

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

NRTI

safe

NEVIRAPINE

Induces CYP3A4 decreasing levels of many drugs Can cause severe skin reactions and hepatotoxicity.

NNRTI

safe

NEVIRAPINE TABLETS FOR ORAL SUSPENSION

Induces CYP3A4 decreasing levels of many drugs Can cause severe skin reactions and hepatotoxicity.

NNRTI

safe

ODEFSEY

Comprehensive clinical and safety monograph for ODEFSEY (ODEFSEY).

HIV Antiretroviral (NNRTI + NRTI Combination)

caution

PIFELTRO

Comprehensive clinical and safety monograph for PIFELTRO (PIFELTRO).

NNRTI

caution

RESCRIPTOR

Comprehensive clinical and safety monograph for RESCRIPTOR (RESCRIPTOR).

NNRTI Antiretroviral

caution

RILPIVIRINE

Proton pump inhibitors are contraindicated as they significantly decrease levels Can cause depressive disorders and hepatotoxicity.

NNRTI

safe

RILPIVIRINE HYDROCHLORIDE

Proton pump inhibitors are contraindicated as they significantly decrease levels Can cause depressive disorders and hepatotoxicity.

NNRTI

safe

STAVUDINE

Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.

NRTI

safe

STAVUDINE; LAMIVUDINE

Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.

NRTI

safe

STAVUDINE; LAMIVUDINE W/NEVIRAPINE

Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.

NRTI

safe

STAVUDINE; LAMIVUDINE; EFAVIRENZ

Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.

NRTI

safe

STAVUDINE; LAMIVUDINE; NEVIRAPINE

Other drugs that cause peripheral neuropathy or pancreatitis increase risk Can cause peripheral neuropathy and pancreatitis.

NRTI

safe

STAVZOR

Comprehensive clinical and safety monograph for STAVZOR (STAVZOR).

NRTI Antiretroviral

caution

SYMFI

Comprehensive clinical and safety monograph for SYMFI (SYMFI).

Antiretroviral NNRTI-Based Combination

caution

SYMFI LO

Comprehensive clinical and safety monograph for SYMFI LO (SYMFI LO).

Antiretroviral NNRTI-Based Combination

caution

TEMIXYS

Comprehensive clinical and safety monograph for TEMIXYS (TEMIXYS).

Antiretroviral (NRTI combination)

caution

TENOFOVIR ALAFENAMIDE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

TENOFOVIR ALAFENAMIDE FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

TENOFOVIR DISOPROXIL FUMARATE

Other nephrotoxic drugs increase risk of renal impairment Can cause renal impairment and decreased bone mineral density.

NRTI

safe

Tenofovir-Lamivudine-Efavirenz

Standard first-line ART for HIV-positive pregnant women per WHO 2021 guidelines. Tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + efavirenz (EFV) as a fixed-dose combination. Efavirenz was historically avoided in T1 due to neural tube defect risk in animal studies; large human registry data (>2,000 T1 exposures) have not confirmed this risk in humans. WHO and UNAIDS now endorse EFV-based regimens throughout pregnancy. Starting or continuing ART is critical to prevent mother-to-child transmission (MTCT) of HIV — benefits far outweigh any theoretical risks.

NRTI

safe

TRIZIVIR

Comprehensive clinical and safety monograph for TRIZIVIR (TRIZIVIR).

Nucleoside Reverse Transcriptase Inhibitor (NRTI) Combination

caution

TRUVADA

Comprehensive clinical and safety monograph for TRUVADA (TRUVADA).

Antiretroviral Combination (NRTI)

caution

VEMLIDY

Comprehensive clinical and safety monograph for VEMLIDY (VEMLIDY).

Nucleoside Reverse Transcriptase Inhibitor (NRTI) for HBV

caution

VIRAMUNE

Comprehensive clinical and safety monograph for VIRAMUNE (VIRAMUNE).

Antiretroviral (NNRTI)

caution

VIRAMUNE XR

Comprehensive clinical and safety monograph for VIRAMUNE XR (VIRAMUNE XR).

Antiretroviral (NNRTI)

caution

ZERIT

Comprehensive clinical and safety monograph for ZERIT (ZERIT).

Antiretroviral (NRTI)

caution

ZERIT XR

Comprehensive clinical and safety monograph for ZERIT XR (ZERIT XR).

Antiretroviral (NRTI)

caution

ZIAGEN

Comprehensive clinical and safety monograph for ZIAGEN (ZIAGEN).

Antiretroviral (NRTI)

caution

ZIDOVUDINE

Other bone marrow suppressants may have additive effects Can cause severe myelosuppression and myopathy.

NRTI

safe